News

 Fourth quarter normalized net income increased by 39%, excluding one-time chargesDeclares Regular Quarterly Cash Dividend Jerusalem, Israel, February 22, 1999 -- Teva Pharmaceutical Industries Ltd., (Nasdaq: TEVIY) today reported financial results for the year and fourth quarter ended December 31, 1998. For the year ended December 31, 1998, total consolidated sales amounted to $1.116 billion, as compared to $1.117 billion in 1997. On a normalized basis, (factoring out a number of restructuring and other special charges in both 1998 and 1997 as discussed below), net income in 1998 amounted to Read More »

Jerusalem, Israel, March 25, 1999 -- Teva Pharmaceutical Industries Ltd., (Nasdaq: TEVIY) is pleased to announce that it has entered into a settlement agreement with respect to two class actions filed in the Tel Aviv District Court against the Company, by holders of Company warrants. These warrants, which were offered in Israel to residents of Israel only, expired on December 31, 1991. Under the terms of the agreement, the claimants will receive up to $9.3 million in cash compensation from Teva's insurers and will be entitled to exercise a portion of the original warrants, which based on today Read More »

  March 31 Dec. 31   1999 1998 1998   U.S. Dollars   (unaudited) (audited) Assets       Current Assets       Cash and cash equivalents 69,780 60,927 47,074 Short-term investments 2,100 4,643 2,148 Accounts receivable:       Trade 263,033 226,361 274,592 Other 87,907 56,610 99,182 Inventories 350,187 300,801 353,249 Total current assets 773,007 649,342 776,245 investments and non-current receivables: 31,839 25,203 32,566         property, plant and equipment:       Cost 755,654 672,050 754,6 Read More »

 Declares Regular Quarterly Cash Dividend Jerusalem, Israel, May 6, 1999 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVIY) today reported financial results for the first quarter ended March 31, 1999 Reported net income for the 1999 first quarter, amounted to $28.3 million, or $0.46 per ADR, as compared to $25.1 million or $0.41 per ADR, reported for the first quarter of 1998. Total sales for the first quarter ended March 31, 1999 were $287.6 million, as compared to $268.6 million in the first quarter of 1998. Eli Hurvitz, President and Chief Executive Officer, commented, "We are very Read More »

 First western european approval for copaxoneÒ Jerusalem, Israel, May 11, 1999- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVIY) announced today at its investor seminar and field trip in Hungary that the Swiss Intercantonal Medicines Control office, the IKS, has granted marketing clearance for CopaxoneÒ for the treatment of Relapsing-Remitting Multiple Sclerosis (RRMS). This is CopaxoneÒ's first Western European approval. With the addition of Switzerland, Copaxone is now approved in 14 countries. The approved Multiple Sclerosis therapeutic indication is for the reduction of frequency of rel Read More »

Jerusalem, Israel, May 18, 1999 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVIY) announced that further to Teva's announcement of March 25, 1999, regarding the class action lawsuits that were filled against Teva and other parties in the District Court in Tel Aviv in January, 1992, the Court issued formal judgments on May 11, 1999, and May 16, 1999, approving the settlement agreement between the parties. Safe Harbor Statement: This release contains forward-looking statements which express the beliefs and expectations of management. Such statements are based on current expectations and invo Read More »

 Declares Regular Quarterly Cash Dividend Jerusalem, Israel, July 29, 1999 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVIY) today reported financial results for the second quarter and six months ended June 30, 1999. Reported net income for the second quarter ended June 30, 1999, rose 82% to $31.1 million, or $0.49 per ADR, as compared to $17.1 million, or $0.28 per ADR, reported for the second quarter of 1998. During the quarter, Teva's profit margin improved to 11% from 7% in the second quarter of 1998. Total sales for the 1999 second quarter rose 19% to $293.7 million, compared to $247. Read More »

Strengthens Teva-USA's Leadership in the U.S. Generic Market Jerusalem, Israel and Canton, MA, August 10, 1999 - Teva Pharmaceutical Industries Ltd, (Nasdaq: TEVIY) and Copley Pharmaceutical, Inc. (Nasdaq: CPLY) announced today that Copley and Teva Pharmaceuticals USA, Inc., Teva's U.S. subsidiary, have executed a definitive merger agreement providing for the acquisition by Teva-USA of all the outstanding shares of Copley for $11.00 per share in cash. The transaction is valued at approximately $220 million. The merger agreement provides for a cash tender offer by Caribou Merger Corporation, a Read More »

Jerusalem, Israel, September 14, 1999 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that its indirect wholly owned subsidiary Caribou Merger Corporation has accepted for payment approximately 18,900,000 shares of common stock of Copley Pharmaceutical, Inc. (Nasdaq: CPLY), representing approximately 93.8 % of the outstanding shares of Copley Pharmaceutical, Inc. (including approximately 550,000 tendered by means of guaranteed delivery), at $11.00 per share in cash in accordance with its tender offer for all outstanding shares of Copley Pharmaceutical, Inc. Approximately 1 Read More »

Jerusalem, Israel, September 30, 1999 -- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and Bio-Technology General Corp. (Nasdaq: BTGC) announced that they have entered into a strategic alliance that will focus on the development and global commercialization of several generic recombinant therapeutic products. The agreement provides for each of the two companies to capitalize on their particular strengths. BTG's primary role will be to develop and manufacture the products, and Teva will have exclusive marketing rights. The agreement calls for Teva to make payment to BTG of up to US $20 mil Read More »